Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Autifony Therapeutics Ltd.
DescriptionPotassium channel Kv3 modulator
Molecular Target Potassium channel Kv3
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today